Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02463214
Other study ID # H15-00662
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2015
Est. completion date March 2018

Study information

Verified date April 2019
Source University of British Columbia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study involves sampling bone marrow transplant patients, hospital workers and the patient room for microbes using swabs and other techniques. We send these samples to the laboratory, where they will use state-of-the art technology to identify and relate the microbes to each other. This study also involves putting copper, nickel, or titanium into some hospital rooms, and seeing whether these metals influences the growth of microbes. Some equipment in the hospital room, such as faucets and soap dispensers will be replaced by sensor-based (e.g. touchless) controls.


Description:

Bacteria and other microbes are everywhere, the majority of which are harmless. They live on our bodies, on everyday objects, in food, and in our environment. They are passed around through the many interactions with other people and our surroundings. Some are even beneficial, helping us digest our food or protecting us from infections caused by harmful microbes.

In rare instances, some of the harmful microbes can cause infections. When a microbe causes an infection while we are in healthcare facilities, they are called "Healthcare-associated infections", or "HAIs". Examples that you may have heard of include Clostridium difficile, and MRSA (methicillin-resistant Staphylococcus aureus). Vancouver General Hospital already has some of the lowest HAI rates in the country. We have dedicated hospital workers that do a great job at preventing HAIs, but we are always looking for ways to be even better.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date March 2018
Est. primary completion date March 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 75 Years
Eligibility Inclusion Criteria (Patients):

- undergoing allogenic bone marrow transplant for acute myeloid leukemia

- will be admitted to the leukemia and bone marrow transplant service at Vancouver General Hospital

- admission to the ward anticipated to be approximately 28 days

Exclusion Criteria (Patients):

- allergies to copper, nickel or titanium

- patients admitted for stays anticipated to be less than 28 days

Inclusion Criteria (Health care worker):

- undergoing allogenic bone marrow transplant for acute myeloid leukemia

- caring for patient enrolled in the study as a primary nurse

Exclusion Criteria (Health care worker):

- allergies to copper, nickel or titanium

Study Design


Intervention

Other:
Engineered Room
Touchless devices: Hand sanitizers, faucets, paper towel dispensers, call devices, Ultraviolet C Aseptix™ Disinfection devices above bathroom doors Copper products: Room and bathroom entrance door hardware, over bed table and bed side table surfaces, chair metal arms, wardrobe handles and knobs, weigh scale, sinks, grab bars, light switch panels, toilet flush handles, faucets and handles, patient bed rails. Titanium dioxide paint: Room walls, head walls, light switches, bathroom wall shelves, toilet tank and bowl, head wall unit fixed equipment, television remote and Bed Control remote

Locations

Country Name City State
Canada Vancouver General Hospital Vancouver British Columbia

Sponsors (2)

Lead Sponsor Collaborator
University of British Columbia Vancouver Coastal Health Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in bioburden on surfaces Looking to see the effectiveness of copper and titanium on the microbiota in the environment of the recovery room. up to 28 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05047406 - Bacillus Clausii in Liver Transplantation Phase 2
Recruiting NCT05198570 - Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
Completed NCT01808456 - Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant. Phase 4
Suspended NCT01301118 - Graft Take and Microbiology in Burns N/A
Completed NCT00610961 - Induction Related BK Viremia in Renal Transplant Patients Phase 4
Recruiting NCT05215327 - High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients Phase 2
Recruiting NCT05193058 - Description of Lung Transplant Patients With Microbiologically Documented Stenotrophomonas Maltophilia Pneumonia and Impact of Treatment on Outcome
Unknown status NCT01983761 - Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation Phase 1/Phase 2
Active, not recruiting NCT02811835 - TransplantLines Food and Nutrition Biobank and Cohort Study (TxL-FN) N/A
Completed NCT01471444 - Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Phase 3
Enrolling by invitation NCT01349738 - Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants N/A
Terminated NCT00473824 - Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation Phase 2
Completed NCT00177801 - Organ Transplant Infection Prevention and Detection Project Phase 4
Completed NCT01276457 - Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients Phase 3
Completed NCT02328963 - Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A Phase 4
Recruiting NCT04320303 - CMV Infection and Immune Intervention After Transplantation N/A
Active, not recruiting NCT01295645 - Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis Phase 2
Completed NCT02329808 - Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics
Completed NCT01471067 - Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies Phase 1
Recruiting NCT04579471 - Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study